^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 L755S

    i
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (NCI-2022-04099) (NCT05372614)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/05/2022
    Primary completion :
    06/17/2024
    Completion :
    06/17/2024
    HER-2 • CD4 • CASP3
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA
    |
    Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (NCI-2017-00831) (NCT03066206)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • HER-2
    |
    EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation
    |
    Pozenveo (poziotinib)
    Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers (NCT02675829)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    02/01/2016
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    HER-2 • MUC16
    |
    HER-2 amplification • HER-2 L755S • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 A775 • HER-2 YVMA
    |
    Kadcyla (ado-trastuzumab emtansine)
    Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer (NCT02673398)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    06/16/2023
    Initiation :
    12/02/2016
    Primary completion :
    03/12/2020
    Completion :
    09/22/2022
    ERBB3
    |
    HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S
    |
    Nerlynx (neratinib)